Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice.

Mucci A, Lopez-Rodriguez E, Hetzel M, Liu S, Suzuki T, Happle C, Ackermann M, Kempf H, Hillje R, Kunkiel J, Janosz E, Brennig S, Glage S, Bankstahl JP, Dettmer S, Rodt T, Gohring G, Trapnell B, Hansen G, Trapnell C, Knudsen L, Lachmann N, Moritz T.

Stem Cell Reports. 2018 Sep 11;11(3):696-710. doi: 10.1016/j.stemcr.2018.07.006. Epub 2018 Aug 9.

2.

Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.

Mucci A, Kunkiel J, Suzuki T, Brennig S, Glage S, Kühnel MP, Ackermann M, Happle C, Kuhn A, Schambach A, Trapnell BC, Hansen G, Moritz T, Lachmann N.

Stem Cell Reports. 2016 Aug 9;7(2):292-305. doi: 10.1016/j.stemcr.2016.06.011. Epub 2016 Jul 21.

3.

Monocyte/macrophage lineage commitment and distribution are affected by the lack of regulatory T cells in scurfy mice.

Skuljec J, Cabanski M, Surdziel E, Lachmann N, Brennig S, Pul R, Jirmo AC, Habener A, Visic J, Dalüge K, Hennig C, Moritz T, Happle C, Hansen G.

Eur J Immunol. 2016 Jul;46(7):1656-68. doi: 10.1002/eji.201546200. Epub 2016 May 27.

4.

Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).

Brennig S, Lachmann N, Buchegger T, Hetzel M, Schambach A, Moritz T.

J Exp Clin Cancer Res. 2015 Dec 12;34:148. doi: 10.1186/s13046-015-0260-4.

5.

Tightly regulated 'all-in-one' lentiviral vectors for protection of human hematopoietic cells from anticancer chemotherapy.

Lachmann N, Brennig S, Hillje R, Schermeier H, Phaltane R, Dahlmann J, Gruh I, Heinz N, Schiedlmeier B, Baum C, Moritz T.

Gene Ther. 2015 Nov;22(11):883-92. doi: 10.1038/gt.2015.61. Epub 2015 Jun 30.

PMID:
26125609
6.

Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.

Lachmann N, Czarnecki K, Brennig S, Phaltane R, Heise M, Heinz N, Kempf H, Dilloo D, Kaever V, Schambach A, Heuser M, Moritz T.

Leukemia. 2015 Nov;29(11):2266-9. doi: 10.1038/leu.2015.108. Epub 2015 Apr 29. No abstract available.

PMID:
25921248
7.

Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies.

Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C, Hoffmann D, Klimenkova O, Lüttge D, Buchegger T, Kühnel MP, Schambach A, Janciauskiene S, Figueiredo C, Hansen G, Skokowa J, Moritz T.

Stem Cell Reports. 2015 Feb 10;4(2):282-96. doi: 10.1016/j.stemcr.2015.01.005.

8.

Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis.

Happle C, Lachmann N, Škuljec J, Wetzke M, Ackermann M, Brennig S, Mucci A, Jirmo AC, Groos S, Mirenska A, Hennig C, Rodt T, Bankstahl JP, Schwerk N, Moritz T, Hansen G.

Sci Transl Med. 2014 Aug 20;6(250):250ra113. doi: 10.1126/scitranslmed.3009750.

9.

Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter.

Phaltane R, Lachmann N, Brennig S, Ackermann M, Modlich U, Moritz T.

Biomaterials. 2014 Aug;35(25):7204-13. doi: 10.1016/j.biomaterials.2014.05.001. Epub 2014 May 27.

PMID:
24875758
10.

Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis.

Lachmann N, Happle C, Ackermann M, Lüttge D, Wetzke M, Merkert S, Hetzel M, Kensah G, Jara-Avaca M, Mucci A, Skuljec J, Dittrich AM, Pfaff N, Brennig S, Schambach A, Steinemann D, Göhring G, Cantz T, Martin U, Schwerk N, Hansen G, Moritz T.

Am J Respir Crit Care Med. 2014 Jan 15;189(2):167-82. doi: 10.1164/rccm.201306-1012OC.

PMID:
24279725
11.

Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Lachmann N, Brennig S, Phaltane R, Flasshove M, Dilloo D, Moritz T.

Neoplasia. 2013 Mar;15(3):239-48. Review.

12.

Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system.

Lachmann N, Brennig S, Pfaff N, Schermeier H, Dahlmann J, Phaltane R, Gruh I, Modlich U, Schambach A, Baum C, Moritz T.

Gene Ther. 2013 Mar;20(3):298-307. doi: 10.1038/gt.2012.40. Epub 2012 May 17.

PMID:
22592598
13.

In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application.

Brennig S, Rattmann I, Lachmann N, Schambach A, Williams DA, Moritz T.

Cytotherapy. 2012 Apr;14(4):451-60. doi: 10.3109/14653249.2011.646043. Epub 2012 Jan 16.

PMID:
22242831
14.

MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy.

Lachmann N, Jagielska J, Heckl D, Brennig S, Pfaff N, Maetzig T, Modlich U, Cantz T, Gentner B, Schambach A, Moritz T.

Gene Ther. 2012 Sep;19(9):915-24. doi: 10.1038/gt.2011.148. Epub 2011 Oct 6.

PMID:
21975463

Supplemental Content

Loading ...
Support Center